

Closing of the first stage of the binding agreement of investment in and acquisition in stages of IOptima

Tel Aviv (March 29, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOptima Ltd. (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), the first stage in the Agreement was completed today, whereby a total direct investment of US\$7 million was invested in IOptima by the Acquirer, at a pre-money valuation of US\$30 million.

Following the completion of the first stage, BioLight holds approximately 57% of the issued and outstanding share capital of IOptima (and approx. 55% on a fully diluted basis).

Pending closings pre conditions, the execution of the second, third and forth stages of the Agreement, the Acquirer will purchase the entire IOptima shares from all its other shareholders (including BioLight)

